Becker's ASC Review

March_April_2019_ASC

Issue link: https://beckershealthcare.uberflip.com/i/1094308

Contents of this Issue

Navigation

Page 42 of 63

43 ORTHOPEDICS 'Doing the right thing:' Ohio surgeons to open orthopedic surgery center By Angie Stewart A kron, Ohio-based The Orthopaedic Surgery Center is constructing a bigger, $7 million facil- ity in Boardman, Ohio, The Vindicator reports. What you should know: 1. The groundbreaking is scheduled for Jan. 23. The nearly 13,000-square-foot facility will sit on 8.6 acres. 2. It will feature four operating rooms and three over- night suites. 3. The Orthopaedic Surgery Center's physicians trav- eled around the country to learn from other outpatient surgery practices. 4. Led by Vice President Thomas Joseph, MD, center physicians specialize in hand, foot and ankle surgeries, shoulder and knee replacements, arthroscopic surgery and pain management. 5. The practice opened in 2003 and launched the area's first outpatient joint replacement program in January 2015. "Lower cost and high-quality care equals responsible medicine. It is about doing the right thing," Dr. Joseph told The Vindicator. n Tulsa Bone & Joint Associates breaks ground on surgery center — 6 insights By Eric Oliver T ulsa (Okla.) Bone & Joint Associates broke ground on the Union Pines Surgery Center and a campus expan- sion Jan. 15. What you should know: 1. Union Pines Surgery Center will offer 23:59 care. 2. The surgery center will also offer optional overnight stays in a separate but onsite "stay center." 3. The new surgery center will feature eight operating rooms, two pain management rooms, 16 preoperative and postoperative patient rooms and five beds for 24-hour stays. 4. The stay center will have 11 overnight rooms, a lobby, a cafe and a conference room. 5. The new surgery center will allow Tulsa Bone & Joint As- sociates the opportunity to perform joint replacement and adult reconstruction procedures, among other orthopedic procedures. 6. Tulsa Bone & Joint Associates entered into a joint ven- ture with Tulsa, Okla.-based St. John Medical Center for the project. n Why Johnson & Johnson CEO Alex Gorsky is bullish on orthopedic performance improvement: 5 things to know By Laura Dyrda J ohnson & Johnson reported orthope- dics sales decreased 1 percent in the fourth quarter of 2018 to $2.2 billion; for the full year, orthopedic sales dipped 1.9 percent to $8.8 billion. Despite the flat sales, Chairman and CEO Alex Gorsky is optimistic about the ortho- pedics line going forward, given demand for implants and innovations coming down the pipeline. Mr. Gorsky and Executive Vice President and CFO Joseph Wolk spoke about orthopedics and spine during the 2018 earn- ings call yesterday. Five quotes to know, as transcribed by Seek- ing Alpha: Alex Gorsky on improving in orthopedics: "ere are areas where we must and we will improve, specifically in orthopedics. We demonstrated positive progress throughout 2018 in our knees and spine businesses, and we believe this sets us up well for 2019 and beyond." AG on future product launches: "ere's a number of reasons why we believe we're going to see improving performance across [the orthopedic] platform and the continued launch of Attune Revision as well as cement- less. We have several additional platforms that we're rolling out that we think will reinforce the profile not only here in North America [but worldwide]." AG on spine: "In spine, we continue to focus on areas such as severe deformity, degenera- tion as well as others. We have a number of new launches that we have coming out including the interbody cage. Biomaterials is an area of interest to us as well." Joseph Wolk on robotics: "If you look a little bit longer term out, we also are looking forward to the addition of robotic digital capabilities with our Orthotaxy platform in orthopedics." AG on Johnson & Johnson's partnership with Apple:"We're very excited about the partnership we have with Apple in this arena, and we think it does represent what we've been talking about for a while in the next step to introducing digital adaptation at almost consumer level…We think this is likely the first of many steps that you'll see not only in our pharma space, but again, our device as well as consumer space in the years to come." n

Articles in this issue

view archives of Becker's ASC Review - March_April_2019_ASC